In oncological drug development, animal studies continue to play a central role in which the 16 volume of subcutaneous tumours is monitored to assess the efficacy of new drugs. Tumour 17 volume is currently estimated by measuring length and width with callipers and then 18 estimating the volume of the tumour as if it were a regular spheroid. However, this method is 19 subjective, insufficiently traceable, and is subject to error in the accuracy of volume 20 estimates as tumours frequently are irregular.
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Abstract 15 In oncological drug development, animal studies continue to play a central role in which the 16 volume of subcutaneous tumours is monitored to assess the efficacy of new drugs. Tumour 17 volume is currently estimated by measuring length and width with callipers and then 18 estimating the volume of the tumour as if it were a regular spheroid. However, this method is 19 subjective, insufficiently traceable, and is subject to error in the accuracy of volume 20 estimates as tumours frequently are irregular.
21
This paper explores the extent of inconsistencies in calliper measurements by conducting a 22 statistical review of a large dataset consisting of 2,500 tumour volume measurements from 23 1,600 mice by multiple operators across 6 mouse strains and 20 tumour models. We also 24 explore the impact of six different tumour morphologies on volume estimation and the 25 detection of treatment effects using a computational tumour growth model. Finally, we 26 propose an alternative method to callipers for estimating volume -BioVolume TM , a 3D 27 scanning technique. BioVolume simultaneously captures both stereo RGB (Red, Green and 28 Blue) images from different light sources and infrared thermal images of the tumour. It 29 detects the tumour region automatically and estimates the tumour volume in under a second.
30
BioVolume has been tested on a dataset of 297 scans from over 120 mice collected by four 31 different operators.
32
This work demonstrates that it is possible to record tumour measurements in a rapid, 33 minimally invasive, morphology-independent way, and with less human-bias compared to
INTRODUCTION
38 Animal models of human cancers are fundamental to our understanding of tumour 39 biology. Tumour volume is a significant metric for preclinical trials where it provides a 40 surrogate measure of both disease progression and treatment efficacy. Thus, accurate and 41 repeatable estimation of tumour volume is crucial to declare a given trial to be a success or 42 failure with confidence (1) . At present, it is standard practice to estimate subcutaneous 43 tumour volume by using callipers to take manual measurements of tumour length and width.
44
This approach erroneously assumes tumours to be regular spheroids (1, (infrared) and 3D surface images. To acquire a scan, the mouse is held such that the tumour 75 region is exposed to the device opening (see Figure 1 , left). Then, acquisition is triggered on 76 either a connected laptop or by using a button on the device itself (see Figure 1 ). There is no 77 requirement to anesthetise the animal. Acquisition takes 0.25s, and rendering occurs in the 
VOLUME CALCULATION

95
We compare two formulae for the estimation of tumour volume: 119 ,
96
and Area-Under-the-Curve (AUC) index:
where "V" denotes volume, t time, area-under-the-curve for treated and control ,
123
(see Appendix 2).
124
A full description of the methods for the analysis of the calliper and BioVolume data can be 125 found in Appendix 1. To assess the impact of using calliper measurements to estimate tumour volume we 158 developed a Cellular Automaton (CA) model of tumour growth and its treatment (see Figure   159 4). 
167
We simulated the growth of both control and treated (10 days treatment, starting on day 15) 168 tumours for each morphology described in Figure 4 . The tumours were subject to simulated most notorious in the early treatment (see Figure 6 ). 
EVALUATION OF BIOVOLUME 194
Consistency between linear measurements 195
We quantified the consistency between the linear length and width measurements made 196 using BioVolume and callipers by making contemporary measurements of a given tumour 197 using both methods and then, for each tumour, counting the number of scan measurements 198 which fell within +/-3mm of the calliper measurements made on the same day. These 199 counts are displayed as histograms for both length ( Figure 7A ) and width ( Figure 7B ).
200
Counts are organised into bins based upon the magnitude of the difference between the 201 calliper and the scan measurements. The vertical grey band highlights values for which this 202 difference was less than or equal to +/-3mm. The 3mm limit has been chosen as a 203 representative figure of the standard deviation of the distributions (see Appendix 1). We 204 found the linear scan measurements to be highly consistent with those made using callipers.
205
For length, 88.68% of the scan measurements fell within +/-3mm of their calliper counterpart 206 and the same was true for 90.99% of width measurements. Differences over 8mm were only 207 observed for 2.10% of length measurements and in 0% of cases for width. In these cases, 
Calliper -Scan Volume comparison 217
Volume estimates for callipers and BioVolume were strongly correlated(R 2 =0.77) (Figure 8 ).
218
Notably, BioVolume displayed a systematic tendency to estimate lower tumour volumes than 
Inter-operator variability 230
We computed the inter-operator CV for cylindrical and spheroid volume estimates derived 231 from BioVolume's measurements as well as for the calliper volume estimates from dataset 1
232
(calliper statistical review) and 2 (BioVolume evaluation), see Figure 9 . We find that
233
BioVolume's spheroid estimates are more precise than those of callipers, whereas the 234 cylindrical volume, which incorporates the height of the tumour, is comparable. There are 235 vast differences in precision between the calliper derived estimates from dataset 1 and 11 236 dataset 2, with the former exhibiting greater spread and variability. Scans that were either 237 misaligned or showed an error have been excluded mounting to 109 (38% of Dataset 2).
238 Figure 9 : Inter-operator precision in volume estimates for callipers and BioVolume. Volume estimates for 239 BioVolume correspond to spheroid (equivalent formula to that used for callipers) and cylindrical approximations. 
251
This may have significant implications for the evaluation of trial outcomes. Furthermore, in 252 Figure 3 we observed that there are larger discrepancies between operators in tumour 253 models 4T-1 and A20. This may be partly because these models are known to invade 254 tissues locally; and partly because they were implanted under the mammary fat pad; thereby 
270
Using the prototype BioVolume scanner we were able to replicate calliper length and width 271 measurements to within +/-3mm in over 90% of cases (see Figure 7 ). Thus, both techniques 272 produce comparable linear measurements. Volumes estimated using BioVolume were highly 273 correlated to those estimated with callipers but were lower on average. Hence, given the 274 trend observed in Figure 3 , there is the possibility that BioVolume's estimates will more 275 closely correspond to excised tumour weight. This implies that BioVolume may be capable of 276 greater accuracy than callipers, but we were unable to make a direct comparison between 277 the volume estimates of BioVolume and tumour weight during the evaluation study.
278
Juxtaposing Figure 3 and Figure 8 , we can infer that BioVolume's estimates, while lower 279 than callipers, would still provide overestimates of weight. This is beneficial in practice as it 280 minimises the risk that tumour burden limits will be exceeded. Further work needs to be 281 performed to validate the performance of BioVolume. Specifically, direct comparisons with 282 imaging techniques such as US, MRI or CT would provide useful insight into the accuracy of 283 the device's estimates.
284
Finally, the inter-operator variability of BioVolume outperforms that of callipers when using 285 the spheroid formula for volume estimation. When tumour height is introduced (via the 286 cylindrical formula, see Figure 9 and Figure S9 in Appendix 1) inter-operator variability is 287 comparable between callipers and BioVolume. This is in part due to the fitting of the back of 288 the mouse, the fitting of the plane to find the normal and the choice of the top point. Small 289 variations in any of these aspects will negatively impact the consistency of height 13 290 measurements. In future versions of BioVolume, we aim to improve upon these issues and 291 to introduce a volume calculation based upon the integration of the complete surface of the 292 tumour. We excluded 109 anomalous scans from our analysis. These anomalies arose due 293 to system errors, misalignment of the thermal/RGB images, or motion blurring. Work is 294 ongoing to prevent such occurrences in the future by i) improving the robustness of the code 295 and ii) by improving the training protocol provided to experimenters using BioVolume.
296
BioVolume, in its current form, presents a promising alternative to callipers. It has the scope 297 to provide accurate measurements with reduced human bias. Furthermore, measurements 298 are fully traceable as images can be revisited at any point post-capture. Additional work is 299 underway to improve BioVolume's performance, and to expand its functionality. For 300 example, machine learning can be applied to classify and characterise the stored tumour 301 images, potentially offering additional biomarkers for treatment efficacy/toxicity and for 302 animal welfare.
303
CONCLUSION
304
In conclusion, the use of linear calliper measurements for tumour volume estimation in 305 lab animals is subject to significant accuracy and reproducibility problems which 306 negatively affect the power of preclinical studies and animal welfare. We proposed
307
BioVolume as an alternative to callipers which provides non-invasive, fully traceable, 308 and more reproducible measurements with the potential to be fully morphology-309 independent and surpass callipers' performance.
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